• 
  Patrick Robelin, Michel Tod, Olivier Colomban, Joel Lachuer, Isabelle Ray-Coquard, et al.. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study). Gynecologic Oncology, 2020, 159, pp.256 - 263. ⟨10.1016/j.ygyno.2020.07.021⟩. ⟨hal-03491450⟩
• 
  Laura Rozenblum, Fatima-Zohra Mokrane, Randy Yeh, Mathieu Sinigaglia, Florent L Besson, et al.. Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach. European Journal of Radiology, 2020, 122, pp.108743. ⟨10.1016/j.ejrad.2019.108743⟩. ⟨hal-02988286⟩
• 
  Marie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, Pierre Feugier, Hervé Maisonneuve, et al.. Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. Blood Advances, 2020, 4 (14), pp.3217-3223. ⟨10.1182/bloodadvances.2020001955⟩. ⟨inserm-03498367⟩
• 
  Maia Chanrion, Inna Kuperstein, Cédric Barrière, Fatima El Marjou, David Cohen, et al.. Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. Nature Communications, 2014, 5, pp.5005. ⟨10.1038/ncomms6005⟩. ⟨hal-01712223⟩
• 
  Gilles Houvenaeghel, Eric Lambaudie, Jean-Marc Classe, Chafika Mazouni, Sylvia Giard, et al.. Lymph node positivity in different early breast carcinoma phenotypes: a predictive model. BMC Cancer, 2019, 19 (1), pp.45. ⟨10.1186/s12885-018-5227-3⟩. ⟨hal-01983749⟩
• 
  Elodie Girard, Séverine Eon‐marchais, Robert E Olaso, Anne‐laure Renault, Francesca Damiola, et al.. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing. International Journal of Cancer, 2019, 144 (8), pp.1962-1974. ⟨10.1002/ijc.31921⟩. ⟨inserm-02438452⟩
• 
  Mary Beth Terry, Yuyan Liao, Karin Kast, Antonis C. Antoniou, Jasmine Mcdonald, et al.. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2 (4), pky078. ⟨10.1093/jncics/pky078⟩. ⟨inserm-02438434⟩
• 
  Mary Beth Terry, Catherine Noguès, Daniel Barrowdale, Debra Frost, Carole Brewer, et al.. Alcohol consumption, cigarette smoking, and risk of breast cancer for BRCA1 and BRCA2 mutation carriers: results from The BRCA1 and BRCA2 Cohort Consortium: Alcohol and smoking and breast cancer risk for BRCA carriers. Cancer Epidemiology, Biomarkers and Prevention, 2019, 27, cebp.0546.2019. ⟨10.1158/1055-9965.EPI-19-0546⟩. ⟨inserm-02438388⟩
• 
  Amélie Guihot, Anne-Geneviève Marcelin, Marie-Ange Massiani, Assia Samri, Cathia Soulié, et al.. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Annals of Oncology, 2018, 29 (2), pp.517-518. ⟨10.1093/annonc/mdx696⟩. ⟨hal-02163559⟩
• 
  Sophie Blein, Laure Barjhoux, Francesca Damiola, Marie-Gabrielle Dondon, Séverine Eon-Marchais, et al.. Targeted Sequencing of the Mitochondrial Genome of Women at High Risk of Breast Cancer without Detectable Mutations in BRCA1/2. PLoS ONE, 2015, 10 (9), pp.e0136192. ⟨10.1371/journal.pone.0136192⟩. ⟨inserm-01991386⟩
• 
  Eve Bureau, Isabelle Pellegrini, Catherine Noguès, Christine Lasset, Claire Julian-Reynier. “Maybe they have found something new” participants’ views on returning cohort psychosocial survey results. Health Expectations, 2015, 18 (6), pp.2425-2436. ⟨10.1111/hex.12211⟩. ⟨inserm-01991364⟩
• 
  Renaud Sabatier, Véronique Diéras, Xavier B. Pivot, Etienne Brain, Henri Roche, et al.. Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. Breast Cancer Research and Treatment, 2018, 50 (4), pp.1226-1237. ⟨10.4143/crt.2017.446⟩. ⟨inserm-01985845⟩
• 
  Jean-Louis Alberini, Raphael Boisgard, Stéphanie Guillermet, Karine Siquier, Benoît Jego, et al.. Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer. Molecular Imaging and Biology, 2016, 18 (4), pp.617-626. ⟨10.1007/s11307-015-0916-7⟩. ⟨hal-01874014⟩
• 
  W. Cacheux, V. Dangles-Marie, E. Rouleau, J. Lazartigues, E. Girard, et al.. Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. Oncotarget, 2018, 9 (1), pp.464-476. ⟨10.18632/oncotarget.23066⟩. ⟨hal-01717339⟩
• 
  Sophie Piperno-Neumann, Marie-Cécile Le Deley, Françoise Rédini, Hélène Pacquement, Perrine Marec-Bérard, et al.. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, 2016, 17 (8), pp.1070-1080. ⟨10.1016/S1470-2045(16)30096-1⟩. ⟨inserm-01702092⟩
• 
  Olga M Sinilnikova, Marie-Gabrielle Dondon, Séverine Eon-Marchais, Francesca Damiola, Laure Barjhoux, et al.. GENESIS: a French national resource to study the missing heritability of breast cancer. BMC Cancer, 2016, 16 (1), pp.606 - 606. ⟨10.1186/s12885-015-2028-9⟩. ⟨hal-01662200⟩
• 
  S. Schorb, C Fox, K Fritsch, L Isbell, N Neubauer, et al.. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. Bone Marrow Transplantation, 2017, 52 (8), pp.1113-1119. ⟨10.1038/bmt.2017.23⟩. ⟨hal-01596402⟩
• 
  Hélène Blons, Etienne Rouleau, Nathanaël Charrier, Gilles Chatellier, Jean-François Côté, et al.. Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.. PLoS ONE, 2013, 8 (7), pp.e68945. ⟨10.1371/journal.pone.0068945⟩. ⟨hal-00974911⟩
• 
  Andrea Toma, O. Kosmider, S. Chevret, J. Delaunay, A. Stamatoullas, et al.. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia, 2016, 30 (4), pp.897--905. ⟨10.1038/leu.2015.296⟩. ⟨hal-01321412⟩
• 
  Alexandra Lapeyre-Prost, Marine Hug De Larauze, Benoist Chibaudel, Marie Line Garcia, Veronique Guering-Meyer, et al.. Feasibility of capecitabine and oxaliplatin combination (XELOX) chemotherapy without central venous access device in patients with stage III colorectal cancer. Clinical Colorectal Cancer, 2016, 15 (3), pp.250-256. ⟨10.1016/j.clcc.2015.11.004⟩. ⟨hal-01239814⟩

34

49